 |
PDBsum entry 1gvz
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.35
- tissue kallikrein.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage of Arg-|-Xaa bonds in small molecule substrates. Highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met-|-Xaa or Leu-|-Xaa. The rat enzyme is unusual in liberating bradykinin directly from autologous kininogens by cleavage at two Arg-|-Xaa bonds.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
322:325-337
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA.
|
|
A.L.Carvalho,
L.Sanz,
D.Barettino,
A.Romero,
J.J.Calvete,
M.J.Romão.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Prostate-specific kallikrein, a member of the gene family of serine proteases,
was initially discovered in semen and is the most useful serum marker for
prostate cancer diagnosis and prognosis. We report the crystal structure at
1.42A resolution of horse prostate kallikrein (HPK). This is the first structure
of a serine protease purified from seminal plasma. HPK shares extensive sequence
homology with human prostate-specific antigen (PSA), including a predicted
chymotrypsin-like specificity, as suggested by the presence of a serine residue
at position S1 of the specificity pocket. In contrast to other kallikreins, HPK
shows a structurally distinct specificity pocket. Its entrance is blocked by the
kallikrein loop, suggesting a possible protective or substrate-selective role
for this loop. The HPK structure seems to be in an inactivated state and further
processing might be required to allow the binding of substrate molecules.
Crystal soaking experiments revealed a binding site for Zn(2+) and Hg(2+), two
known PSA inhibitors.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 5.
Figure 5. Solid-surface representation of HPK. A consensus
substrate peptide (SSYYSG), shown as ball-and-stick, was
positioned, as in model structure 2PSA,[18.] in the specificity
pocket of HPK in an attempt to show the necessary changes for
substrate/serpin binding. In the right-hand picture, the
surfaces corresponding to the kallikrein loop (Leu95A-Ser100)
and to residues Trp215 to Cys220 have been removed, as well as
the catalytic triad residues, which are shown as ball-and-stick
and labelled red. The picture was drawn with GRASP. [53.]
|
 |
Figure 7.
Figure 7. The 2F[o] -F[c] electron density map, contoured
at 1.2s, around the Hg2+-binding region of the Hg-HPK structure,
at 2.3 Å resolution. In the Zn-HPK structure, a zinc atom
is found in the same position, coordinated by the same ligands
(Asp91, His 101, His234) (see bond distances in Table 2). A
probable fourth ligand is a water molecule, which is not
included in the picture. His101 precedes Asp102, which, together
with His57 and Ser195, form the catalytic triad. Asp91 belongs
to the kallikrein loop. The picture was drawn with BOBSCRIPT
[52.] and Raster3D. [51.]
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2002,
322,
325-337)
copyright 2002.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.D.Vogt,
A.Bah,
and
E.Di Cera
(2010).
Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa.
|
| |
J Phys Chem B,
114,
16125-16130.
|
 |
|
|
|
|
 |
A.Pavlopoulou,
G.Pampalakis,
I.Michalopoulos,
and
G.Sotiropoulou
(2010).
Evolutionary history of tissue kallikreins.
|
| |
PLoS One,
5,
e13781.
|
 |
|
|
|
|
 |
C.Eigenbrot,
R.Ganesan,
and
D.Kirchhofer
(2010).
Hepatocyte growth factor activator (HGFA): molecular structure and interactions with HGFA inhibitor-1 (HAI-1).
|
| |
FEBS J,
277,
2215-2222.
|
 |
|
|
|
|
 |
P.Goettig,
V.Magdolen,
and
H.Brandstetter
(2010).
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
|
| |
Biochimie,
92,
1546-1567.
|
 |
|
|
|
|
 |
Z.Chen,
L.A.Pelc,
and
E.Di Cera
(2010).
Crystal structure of prethrombin-1.
|
| |
Proc Natl Acad Sci U S A,
107,
19278-19283.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Bah,
C.J.Carrell,
Z.Chen,
P.S.Gandhi,
and
E.Di Cera
(2009).
Stabilization of the E* form turns thrombin into an anticoagulant.
|
| |
J Biol Chem,
284,
20034-20040.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.Di Cera
(2009).
Serine proteases.
|
| |
IUBMB Life,
61,
510-515.
|
 |
|
|
|
|
 |
P.S.Gandhi,
M.J.Page,
Z.Chen,
L.Bush-Pelc,
and
E.Di Cera
(2009).
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A.
|
| |
J Biol Chem,
284,
24098-24105.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.T.Aminetzach,
J.R.Srouji,
C.Y.Kong,
and
H.E.Hoekstra
(2009).
Convergent evolution of novel protein function in shrew and lizard venom.
|
| |
Curr Biol,
19,
1925-1931.
|
 |
|
|
|
|
 |
A.K.Satheesh Babu,
M.A.Vijayalakshmi,
G.J.Smith,
and
K.C.Chadha
(2008).
Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions.
|
| |
J Chromatogr B Analyt Technol Biomed Life Sci,
861,
227-235.
|
 |
|
|
|
|
 |
J.M.Mattsson,
L.Valmu,
P.Laakkonen,
U.H.Stenman,
and
H.Koistinen
(2008).
Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
|
| |
Prostate,
68,
945-954.
|
 |
|
|
|
|
 |
K.W.Rickert,
P.Kelley,
N.J.Byrne,
R.E.Diehl,
D.L.Hall,
A.M.Montalvo,
J.C.Reid,
J.M.Shipman,
B.W.Thomas,
S.K.Munshi,
P.L.Darke,
and
H.P.Su
(2008).
Structure of human prostasin, a target for the regulation of hypertension.
|
| |
J Biol Chem,
283,
34864-34872.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.A.Borgoño,
J.A.Gavigan,
J.Alves,
B.Bowles,
J.L.Harris,
G.Sotiropoulou,
and
E.P.Diamandis
(2007).
Defining the extended substrate specificity of kallikrein 1-related peptidases.
|
| |
Biol Chem,
388,
1215-1225.
|
 |
|
|
|
|
 |
M.I.Hassan,
V.Kumar,
T.P.Singh,
and
S.Yadav
(2007).
Structural model of human PSA: a target for prostate cancer therapy.
|
| |
Chem Biol Drug Des,
70,
261-267.
|
 |
|
|
|
|
 |
A.Lundwall,
A.Clauss,
and
A.Y.Olsson
(2006).
Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors.
|
| |
Biol Chem,
387,
243-249.
|
 |
|
|
|
|
 |
C.Ferrieu-Weisbuch,
S.Michel,
E.Collomb-Clerc,
C.Pothion,
G.Deléage,
and
C.Jolivet-Reynaud
(2006).
Characterization of prostate-specific antigen binding peptides selected by phage display technology.
|
| |
J Mol Recognit,
19,
10-20.
|
 |
|
|
|
|
 |
M.Debela,
V.Magdolen,
N.Schechter,
M.Valachova,
F.Lottspeich,
C.S.Craik,
Y.Choe,
W.Bode,
and
P.Goettig
(2006).
Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences.
|
| |
J Biol Chem,
281,
25678-25688.
|
 |
|
|
|
|
 |
G.Laxmikanthan,
S.I.Blaber,
M.J.Bernett,
I.A.Scarisbrick,
M.A.Juliano,
and
M.Blaber
(2005).
1.70 A X-ray structure of human apo kallikrein 1: structural changes upon peptide inhibitor/substrate binding.
|
| |
Proteins,
58,
802-814.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.Xie,
and
P.E.Bourne
(2005).
Functional coverage of the human genome by existing structures, structural genomics targets, and homology models.
|
| |
PLoS Comput Biol,
1,
e31.
|
 |
|
|
|
|
 |
M.J.Page,
R.T.Macgillivray,
and
E.Di Cera
(2005).
Determinants of specificity in coagulation proteases.
|
| |
J Thromb Haemost,
3,
2401-2408.
|
 |
|
|
|
|
 |
O.Guvench,
D.J.Price,
and
C.L.Brooks
(2005).
Receptor rigidity and ligand mobility in trypsin-ligand complexes.
|
| |
Proteins,
58,
407-417.
|
 |
|
|
|
|
 |
S.Michel,
E.Collomb-Clerc,
C.Geourjon,
J.P.Charrier,
J.Passagot,
Y.Courty,
G.Deléage,
and
C.Jolivet-Reynaud
(2005).
Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies.
|
| |
J Mol Recognit,
18,
225-235.
|
 |
|
|
|
|
 |
D.Saerens,
J.Kinne,
E.Bosmans,
U.Wernery,
S.Muyldermans,
and
K.Conrath
(2004).
Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen.
|
| |
J Biol Chem,
279,
51965-51972.
|
 |
|
|
|
|
 |
Y.Goumon,
T.Angelone,
F.Schoentgen,
S.Chasserot-Golaz,
B.Almas,
M.M.Fukami,
K.Langley,
I.D.Welters,
B.Tota,
D.Aunis,
and
M.H.Metz-Boutigue
(2004).
The hippocampal cholinergic neurostimulating peptide, the N-terminal fragment of the secreted phosphatidylethanolamine-binding protein, possesses a new biological activity on cardiac physiology.
|
| |
J Biol Chem,
279,
13054-13064.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |